Magellan Health Inc. (NASDAQ:MGLN) previous close was $93.24 while the outstanding shares total 25.45M. The firm has a beta of 1.22, a 12-month trailing P/E ratio of 47.78. MGLN’s shares traded higher over the last trading session, gaining 0.79% on 02/12/21. The shares fell to a low of $93.17 before closing at $93.98. Intraday shares traded counted 0.2 million, which was 43.27% higher than its 30-day average trading volume of 345.57K. The stock’s Relative Strength Index (RSI) is 60.60, with weekly volatility at 0.96% and ATR at 0.90. The MGLN stock’s 52-week price range has touched low of $30.60 and a $95.43 high.
Investors have identified the Healthcare Plans company Magellan Health Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.41 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Magellan Health Inc. (MGLN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For MGLN, the company has in raw cash 152.05 million on their books with 4.31 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 2.29 billion total, with 1.1 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 3.28 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on MGLN sounds very interesting.
Is the stock of MGLN attractive?
In related news, CEO, Magellan Rx Management, Kamal Mostafa sold 2,793 shares of the company’s stock in a transaction that recorded on Dec 09. The sale was performed at an average price of 79.69, for a total value of 222,574. As the sale deal closes, the CEO, Magellan Rx Management, Kamal Mostafa now sold 7,603 shares of the company’s stock, valued at 658,192. Also, CEO, Magellan Rx Management, Kamal Mostafa sold 13,282 shares of the company’s stock in a deal that was recorded on Nov 13. The shares were price at an average price of 83.82 per share, with a total market value of 1,113,318. Following this completion of acquisition, the CEO, Magellan Rx Management, Kamal Mostafa now holds 6,000 shares of the company’s stock, valued at 489,420. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
0 out of 2 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Magellan Health Inc.. 0 analysts has assigned a Sell rating on the MGLN stock. The 12-month mean consensus price target for the company’s shares has been set at $94.00.